Pulmatrix Q2 revenue falls to zero, net loss widens

Pulmatrix

06/08/2025 13:14

Overview

Pulmatrix reports Q2 net loss of $1.55 mln, revenue falls to zero

Company plans to divest inhalation assets amid proposed merger with Cullgen

Proposed merger to create Nasdaq-listed company focused on protein degradation

Outlook

Pulmatrix anticipates merger with Cullgen to close in 2025

Company plans to divest iSPERSE™ technology and clinical programs

Pulmatrix expects cash to fund operations until merger closure

Result Drivers

REVENUE DECLINE - Revenue fell to zero due to completion of PUR1900 Phase 2b trial wind down

EXPENSE REDUCTION - R&D expenses decreased significantly due to trial wind down and lab disposal

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.42
Q2 Net Income
-$1.55 mln
Q2 Income from Operations
-$1.55 mln
Q2 Operating Expenses
$1.55 mln


Press Release: ID:nPn3x1D7da

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)